Ategories. Patients having ER-negative and PR-negative was designated as the ER/PR-negative group, and ER-positive or PR-positive as the ER/PR-positive group. Because significant interactions were observed between ER/PR status and the primary measures, and because the use of adjuvant endocrine therapy and prognosis varies according to ER/PR receptor status, we analyzed data according to ER/PR-posi
Ed two models. Model 1 was constructed using variables with P
Ed two models. Model 1 was constructed using variables with P